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Duodenal mucosal risk markers in patients with
familial adenomatous polyposis: effects of
celecoxib/ursodeoxycholic acid co-treatment and
comparison with patient controls
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Abstract
Background: Familial adenomatous polyposis (FAP) is a disease characterized by the development of hundreds to
thousands of adenomatous polyps in the colorectum early in life. Virtually all patients with FAP will develop
colorectal cancer before the age of 40 to 50 years, unless prophylactic colectomy is performed, which significantly
improves their prognosis. The mortality pattern has changed and duodenal cancer now is one of the main cancer-
related causes of death in these patients. Practically all patients with FAP develop premalignant duodenal
adenomas, which may develop to duodenal cancer in approximately 3-7% of patients. Duodenal cancer in patients
with FAP has a poor prognosis. The clinical challenge is to identify patients at high-risk for duodenal carcinoma.
Chemoprevention would be desirable to avoid duodenectomy. The main goal of this study is to identify risk
markers in normal duodenal mucosa of patients with FAP, that could help identify patients at increased risk for
malignant transformation.
Methods: Messenger RNA (mRNA) levels of glutathione S-transferase A1 (GSTA1), glutathione S-transferase P1
(GSTP1), KIAA1199, E-cadherin, peroxisome proliferative activated receptor δ (PPARδ), caspase-3, cyclin D1, β-catenin,
and cyclooxygenase-2 (COX-2) were measured in duodenal mucosa, using the QuantiGene 2.0 Plex assay. Levels in
normal appearing mucosa of patients with FAP (n = 37) were compared with levels in non-FAP patient controls
(n = 16). In addition, levels before and after treatment with either celecoxib & ursodeoxycholic acid (UDCA, n = 14)
or celecoxib & placebo (n = 13) were evaluated in patients with FAP.
Results: mRNA levels of glutathione S-transferase A1 (28.16% vs. 38.24%, p = 0.008) and caspase-3 (3.30% vs. 5.31%,
p = 0.001) were significantly lower in patients with FAP vs. non-FAP patient controls, respectively. COX-2 mRNA
levels in normal duodenal mucosa of patients with FAP were found to be unexpectedly low. None of the potential
risk markers was influenced by celecoxib or celecoxib & UDCA.
Conclusions: Protection against toxins and carcinogens (GSTA1) and apoptosis (caspase-3) is low in patients with
FAP, which could contribute to increased susceptibility for malignant transformation of duodenal mucosa.
Trial registration: http://ClinicalTrials.gov number NCT00808743
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Background
Familial adenomatous polyposis (FAP), characterized by
the development of numerous premalignant colorectal
adenomatous polyps, is caused by a germline mutation in
the tumor suppressor adenomatous polyposis coli (APC)
gene [1]. In the past decades, preventing development of
colorectal cancer by prophylactic colectomy substantially
improved prognosis in patients with FAP [2]. As a result,
the mortality pattern has changed and duodenal cancer
now is the leading cancer-related cause of death [3,4]. Life-
time risk of duodenal adenomas approaches 100% in pa-
tients with FAP [5], and approximately 3-7% of patients
eventually develop duodenal cancer [6,7]. As duodenal can-
cer in patients with FAP has been associated with a poor
prognosis [8,9], the clinical challenge is to identify patients
with high-risk duodenal adenomas and intervene before
progression to cancer occurs. Identification of early risk
markers in normal duodenal epithelium could help identify
patients at increased risk for malignant transformation.
Potentially useful biomarkers can be expected in cellu-
lar pathways that are linked to the affected APC gene
and its translational product. APC is a multifunctional
protein involved in regulation of cell proliferation, cell
migration, cell adhesion, cytoskeletal reorganisation, and
chromosomal stability [10]. The role of APC in intestinal
carcinogenesis is attributed largely to the Wnt signaling
pathway, but disruption of intercellular adhesion and
stability of the cytoskeleton seems to be involved as well
[11]. Loss of functional APC results in accumulation of
cytosolic β-catenin and subsequent translocation to the
nucleus, where β-catenin associates with members of the
T cell factor (Tcf ) and lymphoid enhancer factor family
(lef ) [11]. The β-catenin/Tcf complex activates several
transcriptional targets, including the G1/S-regulating
cyclin D1 [12] and the peroxisome proliferator-activated
receptor δ (PPARδ) [13]. In addition, β-catenin also
functions as an essential component of epithelial inter-
cellular adherens junctions, where it links the cytoplas-
mic tail of E-cadherin to α-catenin which binds actin
and actin-associated proteins of the microtubule cyto-
skeleton [14]. KIAA1199 was recently described as a
novel target of the Wnt signaling pathway, in both colon
and gastric carcinogenesis [15,16]. While disruptions in
the Wnt signaling pathway are involved in tumor initi-
ation [17], abnormal expression of cyclooxygenase-2
(COX-2) observed in the majority of adenomas and car-
cinomas, is thought to play a crucial role in tumor pro-
gression by increasing the levels of prostaglandin E2
(PGE2) [18]. Overexpression of COX-2 is linked to re-
duced apoptosis, enhanced cell growth, tumor angio-
genesis, and tissue invasion and metastasis [19]. The
involvement of the COX-2/PGE2 pathway may also ex-
plain the observed chemopreventive effects of COX inhi-
biting non-steroidal anti-inflammatory drugs (NSAIDs),
decreasing the occurrence of sporadic colorectal aden-
omas [20,21]. Treatment with the COX-2 selective in-
hibitor celecoxib was found associated with regression of
colorectal adenomas in patients with FAP [22]. Signi-
ficant reduction in duodenal polyp density in patients
with FAP with clinically significant disease was achieved
with high-dose celecoxib [23], a finding we recently con-
firmed [24]. Combining celecoxib with other potentially
effective drugs could reveal more effective strategies.
Based on several preclinical and clinical studies, urso-
deoxycholic acid (UDCA) was a candidate drug [25-29].
However, combining celecoxib with UDCA was found
ineffective in reducing duodenal polyp density in pa-
tients with FAP [24].
The clustering of adenomas around the ampulla of Vater
suggests that cytotoxic bile plays a role in duodenal adeno-
matosis in patients with FAP [30]. Detoxification enzymes,
such as glutathione S-transferases (GSTs), protect the
gastrointestinal mucosa against exogenous and endogen-
ous toxic, mutagenic or carcinogenic compounds by cata-
lyzing the conjugation with glutathione [31]. In patients
with FAP, a significantly lower GST activity was observed
in colonic mucosa as compared to healthy controls [32].
Distorted expression levels of detoxification enzymes in
the duodenum, could reduce functional activity and
modulate individual susceptibility for development of duo-
denal adenomas and carcinomas in patients with FAP.
Aim of the present study was to gain further insight into
the cellular targets of potential chemopreventive treatment
for duodenal adenomatosis in patients with FAP, as well as
to define epithelial risk markers of malignant transform-
ation. We determined messenger RNA (mRNA) expression
levels of potential risk markers in duodenal epithelium of
patients with FAP in comparison to non-FAP patient con-
trols. Furthermore, we investigated the effects of treatment
with celecoxib or celecoxib & UDCA co-treatment on
mRNA expression of these selected biomarkers.
Methods
Study participants
The study population consists of patients with FAP and
non-FAP patient controls. The patients with FAP, recruited
at the Radboud University Nijmegen Medical Centre
(RUNMC), Academic Medical Centre Amsterdam (AMC),
Erasmus Medical Centre Rotterdam (EMC), University
Medical Centre Groningen (UMCG), and Leiden Univer-
sity Medical Centre (LUMC), participated in a double-
blind randomized clinical trial (http://ClinicalTrials.gov
number NCT00808743), which is described in detail else-
where [24]. In short, after completion of pre-intervention
gastroduodenoscopy, patients with FAP were randomly
assigned to one of two treatment groups. Patients in group
A received celecoxib (Celebrex, Pfizer, New York, NY,
USA) 400 mg twice daily for 6 months in combination
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with UDCA (20-30 mg/kg body weight daily; Ursofalk, Dr
Falk Pharma, Freiburg, Germany). Patients in group B re-
ceived celecoxib 400 mg twice daily in combination with
an UDCA identical-appearing placebo (Dr Falk Pharma).
The diagnosis FAP was established either clinically, by the
presence of >100 colorectal polyps, or genetically, by the
presence of adenomatous polyposis coli (APC) gene muta-
tions. Eligible patients were between 18 and 70 years of
age, capable of informed consent, had Spigelman stages II
or III at last surveillance gastroduodenoscopy, and had no
history of surgical duodenal resection.
Patient controls were recruited at the Department of
Gastroenterology, RUNMC. All patients aged 18 to 70 years
and scheduled for diagnostic gastroduodenoscopy because
of dyspepsia, or follow-up after previous diagnosis of upper
gastrointestinal dysplasia or Barrett’s metaplasia, were se-
lected. With permission from the referring physician, pa-
tients received a study information leaflet and an informed
consent form by post. They were contacted by telephone
one week before the planned gastroduodenoscopy to
inquire if additional information was necessary, whether
they were willing to participate, and if so, if any of the ex-
clusion criteria were applicable. Exclusion criteria were:
use of NSAIDs or UDCA for >1 week during 3 months
prior to study entry, history of inflammatory bowel disease,
upper gastrointestinal cancer, upper gastrointestinal sur-
gery, celiac disease, pregnancy, or lactation. Informed con-
sent was obtained prior to gastroduodenoscopy. Patient
controls were compensated for participation with €100.
From all participants, four random biopsies of normal
appearing mucosa were taken in the D2 segment of the
duodenum, as well as four random biopsies in the D3/
D4 segment. An Olympus Endojaw FB-232U with open
forceps diameter 9 mm, or a Boston Scientific Radial Jaw
3 with open forceps diameter 8 mm (Boston Scientific,
Natick, MA, USA) was used. Biopsies were snap frozen
in liquid nitrogen and stored at −80°C for mRNA ana-
lyses. Patients with FAP underwent gastroduodenoscopy
twice: at baseline and after the intervention period.
The present study was conducted according to ICH
Good Clinical Practice and complied with the principles of
the amended Declaration of Helsinki and Dutch legislation.
Ethical approval was obtained at the initiating centre
Radboud University Nijmegen Medical Centre (RUNMC;
number 2008/148; CCMO number NL23569.091.08). All
study participants provided written informed consent. Dis-
closure of randomization was performed by the Department
of Clinical Pharmacy, RUNMC, on December 10th 2012,
after all tissue assessments and analyses were completed.
Isolation of RNA from biopsies and quantification of
duodenal mRNA levels
One biopsy of each location was weighed and taken up in
200 μL TRIzol (Life Technologies, Pailey, UK). Tissue was
homogenized by 10 strokes with a Teflon pestle and after
homogenization another 600 μL TRIzol reagent was
added. Total RNA was extracted according to the manu-
facturer’s instructions (Life Technologies) with a slight
modification as follows: prior to precipitating the RNA
with iosopropyl alcohol, 7.5 μg RNAse-free glycogen was
added as a carrier to the aqueous phase. Approximately
1 μg of total purified RNA was used for the QuantiGene
2.0 Plex assay (Affymetrix, Santa Clara, CA, USA).
RNA was incubated with Luminex beads and capture
probes according to the protocol of the manufacturer.
Target-specific probe sets for beta-2-microglobulin
(β2M, NM_004048), glutathione S-transferase A1 (GSTA1,
NM_145740), glutathione S-transferase P1 (GSTP1,
NM_000852), KIAA1199 (NM_018689), E-cadherin type
1 (CDH1, NM_004360), peroxisome proliferative activated
receptor delta (PPARD, NM_006238), caspase-3 (CASP3,
NM_004346), cyclin D1 (CCND1, NM_053056), beta-
catenin-1 (CTNNB1, NM_001904) and cyclooxygenase-2
(COX-2, NM_000963) were developed by Affymetrix. Sig-
nals of cascade amplification of the fluorescent micro-
spheres were detected by the Biorad Luminex100 Bio-Plex
system using the Bio-Plex Manager 4.1 software (Bio-Rad
Laboratories, Hercules, CA). The mRNA expression level
of the housekeeping gene β2M in each sample was used
for normalization. mRNA levels were expressed as per-
centage relative to the levels of β2M, which were set at
100%. The mean of the mRNA expression levels at the D2
and D3/D4 locations was used in the analyses.
Statistical analysis
Baseline characteristics were expressed as percentage or
medians with range where appropriate. Outcome variables
were expressed as group medians with 25 and 75 percen-
tiles. Differences on discrete variables were examined using
Chi-square test, or Fisher’s exact test when appropriate.
Continuous variables were considered to be not normally
distributed. Differences on continuous variables of base-
line characteristics and outcome measurements between
groups, including measurements in patients with FAP at
baseline versus non-FAP patient controls, and measure-
ments in FAP patients treated with celecoxib & UDCA ver-
sus patients treated with celecoxib & placebo, were tested
using Mann–Whitney U test. Differences within study
groups, comparing pre- and post-intervention measure-
ments in patients with FAP, were examined using Wilcoxon
Signed Rank test. For baseline characteristics, a p-value
of <0.05 (2-sided) was considered statistically significant.
Since each analysis of the outcome measurement com-
prised a set of nine mRNA expression levels, a correction
for multiple testing was applied. In each of these analyses,
a p-value of <0.01 was considered statistically significant.
Statistical analysis was performed using SPSS statistical
software version 21 (IBM SPSS, Chicago, IL, USA).
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Results
Patient characteristics
Patient characteristics of patients with FAP and non-
FAP patient controls are depicted in Table 1. Thirty-
seven patients with FAP were randomized: 19 patients
received celecoxib & UDCA (group A) and 18 patients
received celecoxib & placebo (group B). Nine patients with
FAP (24.3%; group A, n = 5; group B, n = 4) discontinued
intervention prior to post-intervention gastroduodeno-
scopy at 6 months. In one patient in group B, post-
intervention biopsies could not be processed and for this
patient only pre-intervention measurements were in-
cluded in the analyses.
Seventeen non-FAP patient controls underwent gastro-
duodenoscopy as prescribed by the study protocol. One
patient control was excluded from analyses, due to diag-
nosis of celiac disease based on histopathological examin-
ation of the biopsies, and 16 non-FAP patient controls
were included in the analyses. Indications for gastroduo-
denoscopy were dyspepsia (n = 10), iron deficiency anemia
(n = 1), follow-up after previous dysplasia or metaplasia in
the upper gastrointestinal tract (n = 4), and follow-up after
Helicobacter pylori eradication (n = 1).
Patients with FAP vs. non-FAP patient controls
Median mRNA levels of selected genes in endoscopically
normal appearing mucosa of patients with FAP before
clinical intervention (n = 37) were compared with the
levels in non-FAP patient controls (n = 16). Results are
included in Tables 2 and 3.
mRNA levels of GSTA1 and caspase-3 were signifi-
cantly lower in patients with FAP when compared to
levels in non-FAP patient controls (GSTA1: 28.16%
[25-75%: 21.62%-37.90%] vs. 38.24% [27.25%-51.76%];
Mann–Whitney U, p = 0.008); caspase-3: 3.30% [2.46%-
4.68%] vs. 5.31% [4.14%-6.77%]; Mann–Whitney U, p =
0.001). No statistically significant difference in median
duodenal mRNA levels between patients with FAP and
non-FAP patient controls were found for GSTP1,
KIAA1199, E-cadherin-1, PPARδ, cyclin D1, β-catenin-1,
and COX-2.
Patients with FAP pre- vs. post-intervention
Pre- and post-intervention duodenal mRNA levels of se-
lected genes were evaluated in patients with FAP, either
treated with celecoxib & UDCA (group A, n = 14) or cel-
ecoxib & placebo (group B, n = 13). Results are shown in
Tables 2 & 3.
Comparison of median pre-intervention mRNA levels
of the selected genes indicate that no differences existed
at baseline between patients randomly assigned to group
A vs. patients randomly assigned to group B (Mann–
Whitney U, p > 0.05).
The only difference in effect when comparing both
intervention groups was found for E-cadherin type 1
(Mann–Whitney U, p = 0.006). However, when evaluat-
ing the effects within each treatment group, no statisti-
cally significant change in mRNA level after treatment
was observed, given the correction for multiple testing
(group A: median difference = −1.35% [25-75%: -5.00%-
0.68%], Wilcoxon Signed Rank, p = 0.048; group B: me-
dian difference = 1.76% [−0.61%-5.00%], Wilcoxon Signed
Rank, p = 0.064). For any of the other mRNA levels, the
interventions were found to have no statistically signifi-
cant effects.
Table 1 Baseline characteristics of the study population consisting of patients with familial adenomatous polyposis
(FAP) and non-FAP patient controls
Overall non-FAP
group
Overall FAP
group
p-value FAP group A: Celecoxib
& UDCA
FAP group B: Celecoxib
& placebo
p-value
Number of patients 16 37 19 18
Age at study entry, median/range
(yr)
53/23-67 42/22-67 0.092* 42/22-67 41/27-64 0.964*
Sex (n,%) 0.241† 0.618†
Male 5 (31) 18 (49) 10 (53) 8 (44)
Female 11 (69) 19 (51) 9 (47) 10 (56)
Body Mass Index, median/range
(kg/m2)
26.1/19.4-44.2 25.6/18.8-34.5 0.779* 26.0/19.2-34.5 25.6/18.8-33.1 0.408*
Spigelman score at last surveillance
before entry
0.985†
II 19 (51)‡ 10 (53) 9 (50)‡
III 17 (46)‡ 9 (47) 8 (44)‡
*The p-value was calculated by the Mann–Whitney U test.
†The p-value was calculated by the Chi-square test.
‡In 1 case data on Spigelman score at last surveillance gastroduodenoscopy before study entry was missing.
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid.
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Discussion
In the present study, expression of potential risk markers
for malignant transformation were assessed by compar-
ing their mRNA levels in normal appearing duodenal
mucosa of patients with FAP with levels in non-FAP pa-
tient controls. Two important differences were revealed:
duodenal mRNA levels of GSTA1 and caspase-3 were
significantly lower in patients with FAP as compared to
non-FAP patient controls. Lower duodenal levels of the
detoxification enzyme GSTA1 could point at a lower
capacity to detoxify toxins and carcinogens, with subse-
quent increased susceptibility for malignant degener-
ation [31]. Previously, we reported a significantly lower
GST enzyme activity in colonic mucosa of patients with
FAP, as compared to healthy controls [32], but surpris-
ingly, no differences were found in duodenal mucosa of
patients with FAP compared to patient controls [33].
However, the sample size in this study was low (n = 18),
and GSTA1 and GSTA2 were simultaneously measured
at the protein level [33]. In contrast, in the present study
GSTA1 was selectively measured at mRNA level in 37
patients. GSTP1 levels were found to be similar in duo-
denum of patients with FAP and patient controls, which
is in accordance with our previous data [33].
The lower level of caspase-3 found in patients with
FAP, can also be considered as risk marker, as it suggests
a decrease in apoptosis, with subsequent increased sur-
vival of cells with damaged DNA, prone for malignant
Table 2 Duodenal mRNA levels of selected genes
n Messenger RNA
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCND1 CTNNB1 GSTP1
Patient
controls
16 0.04 (0.03-
0.06)
0.05
(0.04-
0.07)
16.43
(11.54-
22.14)
0.73
(0.52-
1.12)
38.24
(27.25-
51.76)
5.31
(4.14-
6.77)
4.20
(2.71-
5.95)
26.90
(21.88-
36.03)
9.69
(6.37-
15.60)
Patients
with FAP
Total Pre-intervention 37 0.05 (0.03-
0.24)
0.04
(0.03-
0.05)
13.36
(10.82-
15.73)
0.71
(0.48-
0.95)
28.16
(21.62-
37.90)
3.30
(2.46-
4.68)
3.72
(3.03-
4.69)
24.84
(19.02-
28.45)
7.64
(5.70-
10.71)
Group A:
Celecoxib &
UDCA
Pre-intervention 19 0.04 (0.02-
0.28)
0.04
(0.03-
0.06)
13.54
(10.90-
18.51)
0.74
(0.54-
1.05)
30.30
(23.16-
36.54)
3.30
(2.47-
5.21)
3.96
(2.63-
4.72)
25.89
(19.80-
31.89)
7.59
(5.78-
11.07)
Post-intervention 14 0.04 (0.02-
0.23)
0.04
(0.03-
0.05)
13.72
(10.46-
15.21)
0.63
(0.50-
1.28)
27.13
(21.28-
33.30)
3.20
(2.88-
4.11)
3.50
(2.81-
5.24)
24.05
(20.96-
30.27)
7.36
(6.22-
10.47)
Group B:
Celecoxib &
placebo
Pre-intervention 18 0.09 (0.03-
0.22)
0.03
(0.02-
0.05)
11.66
(10.28-
15.42)
0.63
(0.45-
0.87)
27.96
(19.84-
39.44)
3.30
(2.42-
4.43)
3.63
(3.18-
4.63)
21.60
(18.63-
27.89)
7.73
(5.46-
10.27)
Post-intervention 13 0.24 (0.05-
0.84)
0.05
(0.03-
0.08)
14.08
(10.79-
16.87)
0.78
(0.58-
1.20)
31.74
(21.02-
47.12)
2.94
(2.58-
4.83)
4.56
(3.09-
5.56)
25.26
(19.93-
33.62)
10.82
(7.44-
16.18)
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; β2M, beta-2-microglobulin; COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1;
PPARD, peroxisome proliferative activated receptor delta; GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1;
GSTP1, glutathione S-transferase P1.
Levels are expressed as median percentage relative to the mRNA level of the housekeeping gene β2M, set at 100%. Values are expressed as mean with 25 and 75
percentiles. For p-values of statistical analyses comparing mRNA levels of selected genes, see Table 3.
Table 3 P-values of statistical analyses comparing duodenal mRNA levels of selected genes
Statistical test P-values
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCND1 CTNNB1 GSTP1
FAP pre-intervention
vs. controls
Mann–Whitney U 0.253 0.021 0.060 0.438 0.008* 0.001* 0.373 0.269 0.104
FAP: pre- vs. post-
intervention
Group A: celecoxib &
UDCA
Wilcoxon Signed
Rank
0.730 0.826 0.048 0.778 0.272 0.074 0.730 0.272 0.433
Group B: celecoxib &
placebo
Wilcoxon Signed
Rank
0.046 0.345 0.064 0.279 0.173 0.600 0.075 0.101 0.013
Group A vs. B: median
of differences
Mann–Whitney U 0.048 0.720 0.006* 0.583 0.048 0.128 0.259 0.043 0.019
*Statistically significant with correction for multiple testing applied (p < 0.01).
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome
proliferative activated receptor delta; GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, glutathione
S-transferase P1.
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degeneration. In a recent study, we were unable to detect
apoptotic cells by immunohistochemistry in the normal
duodenum of patients with FAP [24], which is consistent
with our current finding using mRNA analysis.
Multiple lines of evidence, including results from
in vitro studies, animal studies, as well as clinical studies,
indicate that inhibition of COX-2 expression, at least in
part, accounts for the anti-proliferative activity of cele-
coxib [34]. By using immunohistochemistry, COX-2
overexpression was reported in oesophageal [35], gastric
[36], colorectal [37], and small intestinal cancer [38], as
well as in normal duodenal mucosa of patients with FAP
[39,40]. Moreover, also by immunohistochemistry, COX-
2 levels in normal duodenal mucosa of patients with
FAP were reported to be as high as levels in duodenal
adenomas or carcinomas, and even higher than levels in
normal colonic mucosa [40]. These findings are in sharp
contrast with our results from the mRNA analysis. Al-
though we did find high levels of COX-2 mRNA in nor-
mal colonic mucosa (Roelofs et al., unpublished results),
hardly any mRNA expression was detected in normal
duodenal mucosa of either patients with FAP or non-
FAP patient controls. Similar results using qPCR analysis
to evaluate mRNA expression were previously reported
for small intestinal mucosa of non-FAP individuals [38].
These low levels of COX-2 mRNA in duodenal mucosa,
in contrast to previous reports using immunohistochem-
istry, suggest that COX-2 is of minor importance in the
initial processes of duodenal tumorigenesis in patients
with FAP. Futhermore, the results cast doubt on the spe-
cificity of COX-2 detection by immunohistochemical
staining.
Loss of functional APC in patients with FAP results in
accumulation of cytosolic β-catenin and subsequent
translocation to the nucleus [11], where the β-catenin/
Tcf complex activates cyclin D1 [12] and PPARδ [13].
Our comparison of mRNA levels of cyclin D1 and
PPARδ showed similar values in FAP and non-FAP duo-
denal mucosa (p = 0.37 and p = 0.44, respectively). Using
immunohistochemistry, expression levels of β-catenin
and E-cadherin were found to be lower in normal colon
mucosa of patients with FAP as compared to non-FAP
controls [41]. In addition, we previously described lower
extracellular E-cadherin but higher cytoplasmic β-
catenin expression in normal duodenal mucosa of pa-
tients with FAP, as compared to non-FAP controls [42].
In the current study, analysis of mRNA levels of β-
catenin and E-cadherin markers in normal duodenal
mucosa of patients with FAP and non-FAP patient con-
trols could not confirm the previous immunohistochem-
ical findings.
KIAA1199 was reported as a novel target of the Wnt
signaling pathway and a putative marker for colorectal
and gastic carcinogenic transformation [15,16]. We
assessed KIAA1199 mRNA levels to investigate whether
this marker is also expressed in the normal duodenal
mucosa of patients with FAP with Spigelman grade II or
III adenomatosis, consequently being at substantially in-
creased risk of carcinoma development. However, duo-
denal KIAA1199 levels in normal mucosa of patients
with FAP as well as in non-FAP controls were low and
comparison did not reveal any difference. This could re-
flect the physiologic levels of KIAA1199 present at the
proliferating crypt basis in the duodenal epithelium, as
previously detected in the colonic epithelial crypts [15].
Analysis of KIAA1199 expression in duodenal adenomas
could reveal its involvement in duodenal adenomatous
transformation.
Recently, we reported that celecoxib & placebo, but
not celecoxib & UDCA co-treatment, reduced duodenal
polyp density in patients with FAP [24]. In that study,
cell proliferation, apoptosis and COX-2 expression in
the normal duodenal mucosa of the patients with FAP
were assessed immunohistochemically, but no effects of
celecoxib or celecoxib & UDCA treatment were found.
Here, we quantified mRNA levels of several potential
risk markers, but again, no consistent effects of either of
the two interventions on levels of cell cycle related
markers were observed. We did observe a significant dif-
ference in change in E-cadherin mRNA levels between
both treatment groups, but pre vs. post treatment differ-
ences in E-cadherin mRNA levels were not significantly
different within either of the two treatment groups.
Group comparisons with larger study samples are neces-
sary to elucidate whether actual differences in potential
markers do exist.
The present study has several strengths. First, the
study population of patients with FAP consists of a rela-
tively large and unique sample from 5 out of 8 Dutch
academic medical centers. Second, a new and relatively
simple technique, which is not based on quantitative
polymerase chain reaction (qPCR), is used to measure
mRNA levels of several potential risk markers of interest
simultaneously, in normal duodenal mucosa of patients
with FAP and non-FAP patient controls. The following
limitations are noted. First, the number of non-FAP pa-
tient controls included is relatively small. Consequently,
group comparisons may lack sufficient statistical power
to reveal actual differences, and comparisons in which
no statistically significant difference was observed are
therefore to be interpreted with caution. Second, mRNA
level of each sample was determined as single measure-
ment, however, mean mRNA levels of two different duo-
denal biopsies from the same patient taken at predefined
locations of the duodenum were used in the analyses.
Third, although of great interest, we were not able to as-
sess mRNA expression levels in duodenal adenoma bi-
opsy samples. No biopsy samples of adenomas were
van Heumen et al. Orphanet Journal of Rare Diseases 2013, 8:181 Page 6 of 8
http://www.ojrd.com/content/8/1/181
taken, as pre-intervention sampling of adenomas would
have introduced bias in the primary outcome of the
intervention study [24].
In summary, mRNA levels of nine potential risk pa-
rameters for malignant transformation were assessed in
normal duodenal mucosa of patients with FAP and non-
FAP patient controls. Markers for protection against
toxins and carcinogens (GSTA1) and apoptosis (caspase-
3) were lower in patients with FAP, which could contribute
to the increased susceptibility for malignant transform-
ation of normal duodenal mucosa of patients with FAP.
None of the nine evaluated potential risk markers seem
to be consistently effected by either celecoxib mono-
treatment or celecoxib & UDCA co-treatment. COX-2
levels in normal duodenal mucosa of patients with FAP,
measured at the mRNA level, were found to be very
low, contrasting previous reports of immunohistochem-
ical findings.
Clinical perspective
Chemoprevention would be desirable to avoid duodenect-
omy in patients with FAP. Identification of risk markers in
normal duodenal mucosa could help identify patients at
increased risk for malignant transformation. Messenger
RNA (mRNA) levels of nine potential risk markers were
evaluated. mRNA of glutathione S-transferase A1 (GSTA1)
and caspase-3 were significantly lower in patients with
FAP vs. non-FAP patient controls. Therefore, protection
against toxins and carcinogens (GSTA1) and apoptosis
(caspase-3) seems lower in patients with FAP, which could
contribute to increased susceptibility for malignant trans-
formation of duodenal mucosa. None of the potential risk
markers was consistently influenced by either celecoxib or
celecoxib & UDCA.
Conclusion
Protection against toxins (glutathione S-transferase A1)
and apoptosis (caspase-3) seems lower in normal duodenal
mucosa of patients with FAP, as compared to in patient
controls, which could contribute to the formation of neo-
plasias in the duodenum of patients with FAP.
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